| 1.85 -0.23 (-11.06%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.53 | 1-year : | 2.96 |
| Resists | First : | 2.17 | Second : | 2.53 |
| Pivot price | 1.6  |
|||
| Supports | First : | 1.66 | Second : | 1.35 |
| MAs | MA(5) : | 1.79 |
MA(20) : | 1.58 |
| MA(100) : | 1.97 |
MA(250) : | 2.26 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 80.4 |
D(3) : | 83.9 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 6.92 | Low : | 1.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PYXS ] has closed below upper band by 14.9%. Bollinger Bands are 54.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.11 - 2.12 | 2.12 - 2.13 |
| Low: | 1.77 - 1.78 | 1.78 - 1.79 |
| Close: | 1.83 - 1.85 | 1.85 - 1.86 |
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Tue, 28 Nov 2023
Pyxis Oncology announces appointment of Kobayashi as CMO - Seeking Alpha
Tue, 28 Nov 2023
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer - Yahoo Finance
Tue, 07 Nov 2023
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter ... - GlobeNewswire
Thu, 21 Sep 2023
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible ... - PR Newswire
Sat, 16 Sep 2023
Don't Ignore The Insider Selling In Pyxis Oncology - Simply Wall St
Thu, 07 Sep 2023
Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 30.9 (%) |
| Held by Institutions | 26.2 (%) |
| Shares Short | 801 (K) |
| Shares Short P.Month | 877 (K) |
| EPS | -2.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.9 % |
| Return on Equity (ttm) | -57.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -73 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -0.73 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|